Welcome to our dedicated page for Rafael Holdings SEC filings (Ticker: RFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rafael Holdings, Inc. (RFL) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to its official reports and transaction documents. Rafael Holdings’ filings describe it as a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage pharmaceutical and medical device companies, with a lead program focused on Trappsol® Cyclo™ for Niemann-Pick Disease Type C1.
Key filings include periodic reports and Form 8-K current reports that discuss quarterly and annual financial results, research and development spending, consolidation of subsidiaries such as Cyclo Therapeutics, Cornerstone and Day Three Labs, and capital structure changes. For example, Form 8-K filings detail the completion of a $25 million rights offering of Class B common stock, the issuance and listing of warrants in connection with the Cyclo merger, and subsequent information about those warrants, including their expiration and listing status.
Corporate governance and stockholder matters are documented in the company’s definitive proxy statement (DEF 14A) and related Form 8-Ks, which outline the election of directors, ratification of the independent registered public accounting firm, amendments to the 2021 Equity Incentive Plan and the company’s status as a controlled company under New York Stock Exchange rules. These filings also describe the dual-class share structure and voting rights associated with Class A and Class B common stock.
Investors can also review specialized filings such as Form 25, which in Rafael Holdings’ case relates to the removal from listing and registration of its warrants on NYSE American, and additional 8-Ks that report material events like board changes and executive appointments. On Stock Titan, AI-powered tools can help summarize lengthy documents such as proxy statements and earnings-related 8-Ks, highlight key terms around equity offerings, warrants and governance changes, and make it easier to understand how Rafael Holdings’ clinical focus and portfolio strategy are reflected in its SEC disclosure record.
Rafael Holdings announced that its subsidiary Cyclo Therapeutics has entered into an exclusive licensing agreement with MIT for U.S. Patent No.12285440, covering the use of cyclodextrins in Alzheimer’s Disease patients who carry the ApoE4 genetic mutation.
The company plans to apply this patent to its lead candidate Trappsol® Cyclo™, which is already in a pivotal Phase 3 trial for Niemann-Pick Disease Type C1. The ApoE4 gene variant is estimated to be present in 50-70% of Alzheimer’s patients, and the release highlights preclinical data suggesting Trappsol® Cyclo™ may improve cholesterol transport in the brain, reduce tau pathology, and improve learning and memory in mice. Management also notes Phase 3 results from the Transport NPC study are expected in calendar Q3 2026.
Rafael Holdings, Inc. Chief Financial Officer David Polinsky reported a tax-related share disposition. On the vesting of restricted stock, 2,318 shares of Class B common stock were withheld by the company to cover tax obligations, rather than being sold on the open market.
After this withholding, Polinsky directly and indirectly holds a total of 301,497 shares, consisting of 76,882 shares held directly, 98,365 fully vested restricted shares and 126,250 unvested restricted shares that vest in scheduled installments through 2030. This filing reflects routine compensation and tax treatment rather than a discretionary trade.
Rafael Holdings, Inc. executive chairman, CEO and president Howard S. Jonas reported a Form 4 showing 9,826 shares of Class B common stock withheld by the company at $1.5025 per share to cover taxes upon the vesting of restricted stock. This is recorded as a tax-withholding disposition rather than an open-market trade.
After this event, he directly holds 323,014 Class B shares, consisting of 218,365 vested restricted shares and 104,649 unvested restricted shares that are scheduled to vest in tranches through 2030. He also reports substantial indirect holdings through entities including The Jonas Foundation, the Debbie Y. Jonas 2018 Dynasty Trust, the HSJ 2019 Remainder Trust, and several limited partnerships.
Rafael Holdings, Inc. reported a larger operating loss as it advances its biotech strategy. For the six months ended January 31, 2026, revenue was $451 thousand, up from $205 thousand a year earlier, driven mainly by rental and new product sales, but research and development expense rose to $12.0 million from $2.3 million. Net loss attributable to Rafael Holdings widened to $16.2 million, or $0.32 per share, compared with $13.6 million, or $0.57 per share. Cash and cash equivalents were $37.8 million as of January 31, 2026, down from $52.8 million at prior fiscal year-end, after using $14.3 million in operating cash during the period. Total assets were $99.3 million and equity was $83.3 million, reflecting significant goodwill and in-process R&D tied to its acquisition of Cyclo and lead drug candidate Trappsol® Cyclo™. The company states its cash is expected to cover obligations for at least 12 months while it focuses on completing a pivotal Phase 3 trial in Niemann-Pick Disease Type C1 and managing a portfolio of majority-owned life science businesses.
Rafael Holdings, Inc. reported results for its second quarter of fiscal 2026, ended January 31, 2026, while highlighting progress in its pivotal Phase 3 TransportNPC™ study of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1. An independent Data Monitoring Committee recommended the trial continue after reviewing prespecified safety and efficacy data at 48 weeks, and the company expects to complete the 96-week study and report preliminary top line results in the third quarter of this calendar year.
As of January 31, 2026, cash and cash equivalents were $37.8 million, down from $52.8 million as of July 31, 2025. For the quarter, net loss attributable to Rafael Holdings was $6.4 million, or $0.13 per share, compared with a net loss of $4.6 million, or $0.19 per share, a year earlier. Revenue was $0.2 million, up from $0.1 million in the prior-year quarter, while research and development expenses rose to $4.5 million from $0.9 million, primarily due to consolidating Cyclo Therapeutics’ costs after its March 2025 acquisition. General and administrative expenses decreased to $2.3 million from $2.6 million.
Rafael Holdings director Markus Sieger received a grant of 29,528 shares of Class B common stock on January 28, 2026. The award was structured as restricted stock that, according to the footnotes, vests in full immediately rather than over time.
The grant was valued using an average price of $1.27 per share, based on the issuer’s December 2025 closing prices. Following this equity award, Sieger beneficially owns a total of 219,710 Class B shares, consisting of 29,528 fully vested restricted shares and 190,182 shares held directly.
Rafael Holdings director receives restricted stock grant. Director Michael J. Weiss was awarded 39,370 shares of Rafael Holdings Class B common stock on January 28, 2026, reported as an acquisition transaction.
The grant is in the form of restricted stock that vests in full immediately, meaning the shares are fully earned at the grant date. The filing values the award at an average price of $1.27 per share, based on the issuer’s average December 2025 closing price. Following this grant, Weiss directly beneficially owns 141,861 shares of Class B common stock, consisting entirely of fully vested restricted stock.
Rafael Holdings director Mark N. Stein received a grant of 39,370 shares of Class B common stock as restricted stock that vests in full immediately. The grant was effective on January 28, 2026 at a reference value of $1.27 per share, based on the average closing price during December 2025.
Following this equity award, Stein beneficially owns 50,845 shares of Rafael Holdings Class B common stock in direct ownership, all described as fully vested restricted stock.
Rafael Holdings (RFL) director Alan Grayson reported receiving a grant of 6,562 shares of Class B common stock on January 28, 2026. The filing describes this as restricted stock that vests in full immediately and is now fully vested.
The transaction is coded as an acquisition at a reference price of $1.27 per share, representing the average closing price of the Class B stock during December 2025. Following this grant, Grayson directly holds 6,562 Class B common shares.
Rafael Holdings, Inc. insider filing shows a new equity grant to its top executive. On January 13, 2026, Exec Chairman, CEO & President Howard S. Jonas, who is also a director and 10% owner, received 75,000 shares of Class B common stock as a restricted stock grant at $1.2485 per share. These shares vest in four equal installments of 18,750 shares on each of January 13, 2027, 2028, 2029 and 2030.
Following this grant, Jonas beneficially owns 332,840 Class B shares directly, consisting of 198,542 vested and 134,298 unvested restricted shares with additional vesting dates in 2026 and 2027–2030. The filing also lists substantial indirect holdings in Class B and Class A shares through The Jonas Foundation, several trusts, and limited partnerships, including Rafael A Partners, L.P., where he has sole voting and dispositive power over the Class A shares.